Profiel
Sapan Shah currently works at Glyscend, Inc., as Chief Executive Officer & Director from 2023.
Dr. Shah also formerly worked at Rycarma Therapeutics, Inc., as Chief Executive Officer, Shionogi, Inc., as Chief Executive Officer, and StrideBio, Inc., as Chief Executive Officer.
Dr. Shah received his undergraduate degree from Northwestern University and doctorate degree from Yale University.
Actieve functies van Sapan Shah
| Bedrijven | Functie | Begin |
|---|---|---|
Glyscend, Inc.
Glyscend, Inc. Pharmaceuticals: MajorHealth Technology Develops oral metabolic therapeutics for the treatment of type 2 diabetes | Algemeen Directeur | 05-09-2023 |
Eerdere bekende functies van Sapan Shah
| Bedrijven | Functie | Einde |
|---|---|---|
Shionogi, Inc.
Shionogi, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes antibiotics | Algemeen Directeur | - |
Rycarma Therapeutics, Inc.
Rycarma Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel small-molecule therapeutics | Algemeen Directeur | - |
StrideBio, Inc.
StrideBio, Inc. BiotechnologyHealth Technology Develops gene therapies | Algemeen Directeur | - |
Opleiding van Sapan Shah
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 6 |
|---|---|
Rycarma Therapeutics, Inc.
Rycarma Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel small-molecule therapeutics | Health Technology |
Northwestern University
Northwestern University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Yale University
Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Shionogi, Inc.
Shionogi, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes antibiotics | Health Technology |
StrideBio, Inc.
StrideBio, Inc. BiotechnologyHealth Technology Develops gene therapies | Health Technology |
Glyscend, Inc.
Glyscend, Inc. Pharmaceuticals: MajorHealth Technology Develops oral metabolic therapeutics for the treatment of type 2 diabetes | Health Technology |
















